Osivax
Created in 2017
- BETA
Up & running (A)
Existing signals show a regular activity Social networks
142 5,961Global tags
Activities
Technologies
Entity types
Location
70 Rue Saint-Jean-de-Dieu, 69007 Lyon, France
Lyon
France
Employees
Scale: 11-50
Estimated: 53
SIREN
829604750Engaged corporates
23
11 15Added in Motherbase
2 years, 6 months ago
biotech Value proposition
Pioneering A New Class of Universal Vaccines
Osivax is a clinical-stage biopharmaceutical company leveraging its novel, self-assembling nanoparticle platform technology, oligoDOM, to develop transformative, first-in-class pan-respiratory virus vaccines generating superior T-cell responses in addition to strong and sustained B-cell responses. The company is establishing proof of concept with its broad-spectrum, “universal” influenza candidate, OVX836, which is currently in Phase 2 clinical trials with over 1200 subjects tested and encouraging efficacy proof of concept data. Osivax’ ambition is to develop a pan-respiratory virus vaccine to prevent all strains of influenza and all variants of sarbecovirus in one single shot. The company will expand into other infectious disease indications through combinations and collaborations worldwide.
biotechnology, immunology, antigens, vaccine, Influenza, universal, cellular immune response, CD8 T-cell, Infectious diseases, Immuno-oncology, and covidOriginal language
Pioneering A New Class of Universal Vaccines
Osivax is a clinical-stage biopharmaceutical company leveraging its novel, self-assembling nanoparticle platform technology, oligoDOM, to develop transformative, first-in-class pan-respiratory virus vaccines generating superior T-cell responses in addition to strong and sustained B-cell responses. The company is establishing proof of concept with its broad-spectrum, “universal” influenza candidate, OVX836, which is currently in Phase 2 clinical trials with over 1200 subjects tested and encouraging efficacy proof of concept data. Osivax’ ambition is to develop a pan-respiratory virus vaccine to prevent all strains of influenza and all variants of sarbecovirus in one single shot. The company will expand into other infectious disease indications through combinations and collaborations worldwide.
HOME - Osivax
Osivax is developing a new class of universal vaccines empowering both arms of the immune system.
https://osivax.com/
| Corporate | Type | Tweets | Articles | |
|---|---|---|---|---|
 Boehringer Ingelheim Pharmaceutical, Pharmaceutical Manufacturing, Animal Health | Boehringer Ingelheim Pharmaceutical, Pharmaceutical Manufacturing, Animal Health | Other 29 Nov 2022 | | |
 United Nations Office for Disarmament Affairs International development, International Affairs | United Nations Office for Disarmament Affairs International development, International Affairs | Other 29 Dec 2023 | | |
 Bpifrance Bank, Banking | Bpifrance Bank, Banking | Capitalistic Not partnership Not event 8 Jul 2020 25 Jun 2024 | | |